Point72 Asset Management’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-173,383
| Closed | -$6.62M | – | 4529 |
|
|
2025
Q4 | $6.62M | Buy |
+173,383
| New | +$5.64M | 0.01% | 1624 |
|
|
2025
Q3 | – | Sell |
-167,896
| Closed | -$2.48M | – | 2692 |
|
|
2025
Q2 | $2.48M | Buy |
+167,896
| New | +$2.78M | ﹤0.01% | 1211 |
|
|
2024
Q3 | – | Sell |
-320,580
| Closed | -$2.64M | – | 2357 |
|
|
2024
Q2 | $2.64M | Sell |
320,580
-551,520
| -63% | -$3.71M | 0.01% | 1018 |
|
|
2024
Q1 | $6.72M | Buy |
+872,100
| New | +$7.36M | 0.02% | 872 |
|
|
2023
Q4 | – | Sell |
-13,572
| Closed | -$121K | – | 2836 |
|
|
2023
Q3 | $121K | Sell |
13,572
-1,772,407
| -99% | -$25M | ﹤0.01% | 1913 |
|
|
2023
Q2 | $27.4M | Buy |
+1,785,979
| New | +$32.5M | 0.08% | 307 |
|
|
2022
Q4 | – | Sell |
-327,706
| Closed | -$8.07M | – | 1800 |
|
|
2022
Q3 | $8.07M | Buy |
+327,706
| New | +$8.47M | 0.03% | 572 |
|
|
2022
Q2 | – | Sell |
-33,300
| Closed | -$858K | – | 1643 |
|
|
2022
Q1 | $858K | Buy |
+33,300
| New | +$884K | ﹤0.01% | 982 |
|
|
2021
Q2 | – | Sell |
-1,608,126
| Closed | -$40.2M | – | 1174 |
|
|
2021
Q1 | $40.2M | Buy |
1,608,126
+987,126
| +159% | +$27.3M | 0.19% | 142 |
|
|
2020
Q4 | $16.9M | Sell |
621,000
-420,405
| -40% | -$9.82M | 0.08% | 314 |
|
|
2020
Q3 | $19.2M | Buy |
1,041,405
+655,279
| +170% | +$12.7M | 0.1% | 280 |
|
|
2020
Q2 | $7.88M | Buy |
386,126
+82,746
| +27% | +$1.32M | 0.05% | 390 |
|
|
2020
Q1 | $4.43M | Buy |
+303,380
| New | +$4.56M | 0.04% | 399 |
|
|
2019
Q3 | – | Sell |
-238,900
| Closed | -$4.8M | – | 1477 |
|
|
2019
Q2 | $4.8M | Sell |
238,900
-27,200
| -10% | -$537K | 0.03% | 525 |
|
|
2019
Q1 | $6.02M | Sell |
266,100
-433,900
| -62% | -$9.59M | 0.03% | 520 |
|
|
2018
Q4 | $15.8M | Buy |
700,000
+51,400
| +8% | +$1.28M | 0.08% | 309 |
|
|
2018
Q3 | $18.6M | Buy |
648,600
+223,500
| +53% | +$6.39M | 0.08% | 312 |
|
|
2018
Q2 | $11.6M | Sell |
425,100
-502,300
| -54% | -$13.4M | 0.05% | 413 |
|
|
2018
Q1 | $20.7M | Buy |
927,400
+59,600
| +7% | +$1.42M | 0.09% | 285 |
|
|
2017
Q4 | $18.3M | Buy |
867,800
+392,229
| +82% | +$8.96M | 0.08% | 317 |
|
|
2017
Q3 | $11.8M | Sell |
475,571
-497,929
| -51% | -$11M | 0.05% | 365 |
|
|
2017
Q2 | $18.9M | Buy |
973,500
+8,700
| +0.9% | +$158K | 0.11% | 262 |
|
|
2017
Q1 | $17.8M | Buy |
964,800
+552,065
| +134% | +$10.8M | 0.1% | 269 |
|
|
2016
Q4 | $7.81M | Buy |
412,735
+261,935
| +174% | +$5.36M | 0.05% | 367 |
|
|
2016
Q3 | $3.38M | Sell |
150,800
-24,000
| -14% | -$457K | 0.02% | 490 |
|
|
2016
Q2 | $3.11M | Buy |
+174,800
| New | +$2.83M | 0.02% | 503 |
|
|
2015
Q4 | – | Sell |
-194,000
| Closed | -$3.93M | – | 855 |
|
|
2015
Q3 | $3.93M | Sell |
194,000
-49,300
| -20% | -$1.46M | 0.03% | 460 |
|
|
2015
Q2 | $8.06M | Buy |
+243,300
| New | +$6.66M | 0.06% | 364 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
Point72 Asset Management's TVTX Position: Q1 2026 in Review
Point72 Asset Management sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 173,383 shares — an estimated $6.62M sold.
Point72 Asset Management first reported a position in TVTX in Q2 2015 and held it in 28 quarters. The position peaked at $40.2M in Q1 2021. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- Point72 Asset Management reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
- Point72 Asset Management sold 173,383 Travere Therapeutics shares in Q1 2026, an estimated $6.62M.
- Point72 Asset Management first reported a position in Travere Therapeutics in Q2 2015 and held it in 28 quarters.
- Point72 Asset Management's Travere Therapeutics position peaked at $40.2M in Q1 2021.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.